ID   NCOA6_HUMAN             Reviewed;        2063 AA.
AC   Q14686; A6NLF1; B2RMN5; E1P5P7; Q9NTZ9; Q9UH74; Q9UK86;
DT   12-FEB-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   12-APR-2017, entry version 157.
DE   RecName: Full=Nuclear receptor coactivator 6;
DE   AltName: Full=Activating signal cointegrator 2;
DE            Short=ASC-2;
DE   AltName: Full=Amplified in breast cancer protein 3;
DE   AltName: Full=Cancer-amplified transcriptional coactivator ASC-2;
DE   AltName: Full=Nuclear receptor coactivator RAP250;
DE            Short=NRC RAP250;
DE   AltName: Full=Nuclear receptor-activating protein, 250 kDa;
DE   AltName: Full=Peroxisome proliferator-activated receptor-interacting protein;
DE            Short=PPAR-interacting protein;
DE            Short=PRIP;
DE   AltName: Full=Thyroid hormone receptor-binding protein;
GN   Name=NCOA6; Synonyms=AIB3, KIAA0181, RAP250, TRBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH CREBBP; NCOA1; GTF2A;
RP   TBP; RXRA; ESR1; RARA AND THRA, AND VARIANT SER-955.
RX   PubMed=10567404; DOI=10.1074/jbc.274.48.34283;
RA   Lee S.-K., Anzick S.L., Choi J.-E., Bubendorf L., Guan X.-Y.,
RA   Jung Y.-K., Kallioniemi O.-P., Kononen J., Trent J.M., Azorsa D.,
RA   Jhun B.-H., Cheong J.H., Lee Y.C., Meltzer P.S., Lee J.W.;
RT   "A nuclear factor ASC-2, as a cancer-amplified transcriptional
RT   coactivator essential for ligand-dependent transactivation by nuclear
RT   receptors in vivo.";
RL   J. Biol. Chem. 274:34283-34293(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], HOMODIMERIZATION, INTERACTION WITH CREBBP;
RP   RXRA; ESR1; NR3C1; RARA; VDR AND THRA, AND VARIANT SER-955.
RX   PubMed=10866662; DOI=10.1128/MCB.20.14.5048-5063.2000;
RA   Mahajan M.A., Samuels H.H.;
RT   "A new family of nuclear receptor coregulators that integrates nuclear
RT   receptor signaling through CBP.";
RL   Mol. Cell. Biol. 20:5048-5063(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH PPARA; PPARG; ESR1; ESR2
RP   AND THR, AND VARIANT SER-955.
RC   TISSUE=Testis;
RX   PubMed=10681503; DOI=10.1074/jbc.275.8.5308;
RA   Caira F., Antonson P., Pelto-Huikko M., Treuter E., Gustafsson J.-A.;
RT   "Cloning and characterization of RAP250, a nuclear receptor
RT   coactivator.";
RL   J. Biol. Chem. 275:5308-5317(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], PHOSPHORYLATION BY PRKDC, INTERACTION WITH
RP   THR; RAR; EP300 AND CRSP3, AND VARIANT SER-955.
RC   TISSUE=Lymphocyte;
RX   PubMed=10823961; DOI=10.1073/pnas.97.11.6212;
RA   Ko L., Cardona G.R., Chin W.W.;
RT   "Thyroid hormone receptor-binding protein, an LXXLL motif-containing
RT   protein, functions as a general coactivator.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:6212-6217(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-955.
RC   TISSUE=Bone marrow;
RX   PubMed=8724849; DOI=10.1093/dnares/3.1.17;
RA   Nagase T., Seki N., Ishikawa K., Tanaka A., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. V.
RT   The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 3:17-24(1996).
RN   [6]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH NCOA6IP.
RX   PubMed=11517327; DOI=10.1073/pnas.181347498;
RA   Zhu Y.-J., Qi C., Cao W.-Q., Yeldandi A.V., Rao M.S., Reddy J.K.;
RT   "Cloning and characterization of PIMT, a protein with a
RT   methyltransferase domain, which interacts with and enhances nuclear
RT   receptor coactivator PRIP function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:10380-10385(2001).
RN   [11]
RP   INTERACTION WITH RBM14.
RX   PubMed=11443112; DOI=10.1074/jbc.M101517200;
RA   Iwasaki T., Chin W.W., Ko L.;
RT   "Identification and characterization of RRM-containing coactivator
RT   activator (CoAA) as TRBP-interacting protein, and its splice variant
RT   as a coactivator modulator (CoAM).";
RL   J. Biol. Chem. 276:33375-33383(2001).
RN   [12]
RP   INTERACTION WITH PRMT2.
RX   PubMed=12039952; DOI=10.1074/jbc.M201053200;
RA   Qi C., Chang J., Zhu Y., Yeldandi A.V., Rao S.M., Zhu Y.-J.;
RT   "Identification of protein arginine methyltransferase 2 as a
RT   coactivator for estrogen receptor alpha.";
RL   J. Biol. Chem. 277:28624-28630(2002).
RN   [13]
RP   INTERACTION WITH ZNF335.
RX   PubMed=12215545; DOI=10.1128/MCB.22.19.6883-6894.2002;
RA   Mahajan M.A., Murray A., Samuels H.H.;
RT   "NRC-interacting factor 1 is a novel cotransducer that interacts with
RT   and regulates the activity of the nuclear hormone receptor coactivator
RT   NRC.";
RL   Mol. Cell. Biol. 22:6883-6894(2002).
RN   [14]
RP   IDENTIFICATION IN THE MLL2/3 (ASCOM) COMPLEX.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12482968; DOI=10.1128/MCB.23.1.140-149.2003;
RA   Goo Y.-H., Sohn Y.C., Kim D.-H., Kim S.-W., Kang M.-J., Jung D.-J.,
RA   Kwak E., Barlev N.A., Berger S.L., Chow V.T., Roeder R.G.,
RA   Azorsa D.O., Meltzer P.S., Suh P.-G., Song E.J., Lee K.-J., Lee Y.C.,
RA   Lee J.W.;
RT   "Activating signal cointegrator 2 belongs to a novel steady-state
RT   complex that contains a subset of trithorax group proteins.";
RL   Mol. Cell. Biol. 23:140-149(2003).
RN   [15]
RP   MUTAGENESIS OF 883-THR--GLU-894, AND PHOSPHORYLATION AT SER-884.
RX   PubMed=11773444; DOI=10.1210/mend.16.1.0755;
RA   Ko L., Cardona G.R., Iwasaki T., Bramlett K.S., Burris T.P.,
RA   Chin W.W.;
RT   "Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines
RT   selectivity for ERs and TRs.";
RL   Mol. Endocrinol. 16:128-140(2002).
RN   [16]
RP   IDENTIFICATION IN THE MLL2/3 (ASCOM) COMPLEX.
RX   PubMed=17021013; DOI=10.1073/pnas.0607313103;
RA   Lee S., Lee D.K., Dou Y., Lee J., Lee B., Kwak E., Kong Y.Y.,
RA   Lee S.K., Roeder R.G., Lee J.W.;
RT   "Coactivator as a target gene specificity determinant for histone H3
RT   lysine 4 methyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15392-15397(2006).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MLL2/3
RP   COMPLEX.
RX   PubMed=17500065; DOI=10.1074/jbc.M701574200;
RA   Cho Y.-W., Hong T., Hong S., Guo H., Yu H., Kim D., Guszczynski T.,
RA   Dressler G.R., Copeland T.D., Kalkum M., Ge K.;
RT   "PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4
RT   methyltransferase complex.";
RL   J. Biol. Chem. 282:20395-20406(2007).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2018, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-95, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-1060 AND ARG-1191.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Nuclear receptor coactivator that directly binds nuclear
CC       receptors and stimulates the transcriptional activities in a
CC       hormone-dependent fashion. Coactivates expression in an agonist-
CC       and AF2-dependent manner. Involved in the coactivation of
CC       different nuclear receptors, such as for steroids (GR and ERs),
CC       retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR)
CC       and prostanoids (PPARs). Probably functions as a general
CC       coactivator, rather than just a nuclear receptor coactivator. May
CC       also be involved in the coactivation of the NF-kappa-B pathway.
CC       May coactivate expression via a remodeling of chromatin and its
CC       interaction with histone acetyltransferase proteins.
CC   -!- SUBUNIT: Monomer and homodimer. Interacts with RBM39 (By
CC       similarity). Interacts in vitro with the basal transcription
CC       factors GTF2A and TBP, suggesting an autonomous transactivation
CC       function. Interacts with NCOA1, CRSP3, RBM14, the histone
CC       acetyltransferases EP300 and CREBBP, and with the
CC       methyltransferases NCOA6IP and PRMT2/HRMT1L1. Component of the
CC       MLL2/3 complex (also named ASCOM complex), at least composed of
CC       KMT2D/MLL2 or KMT2C/MLL3, ASH2L, RBBP5, WDR5, NCOA6, DPY30, KDM6A,
CC       PAXIP1/PTIP, PAGR1 and alpha- and beta-tubulin. Interacts with
CC       ZNF335; may enhance ligand-dependent transcriptional activation by
CC       nuclear hormone receptors. {ECO:0000250,
CC       ECO:0000269|PubMed:10567404, ECO:0000269|PubMed:10681503,
CC       ECO:0000269|PubMed:10823961, ECO:0000269|PubMed:10866662,
CC       ECO:0000269|PubMed:11443112, ECO:0000269|PubMed:11517327,
CC       ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12215545,
CC       ECO:0000269|PubMed:12482968, ECO:0000269|PubMed:17021013,
CC       ECO:0000269|PubMed:17500065}.
CC   -!- INTERACTION:
CC       P10275:AR; NbExp=2; IntAct=EBI-78670, EBI-608057;
CC       Q9UBL3:ASH2L; NbExp=11; IntAct=EBI-78670, EBI-540797;
CC       Q92793:CREBBP; NbExp=2; IntAct=EBI-78670, EBI-81215;
CC       Q8NEZ4:KMT2C; NbExp=5; IntAct=EBI-78670, EBI-1042997;
CC       O14686:KMT2D; NbExp=6; IntAct=EBI-78670, EBI-996065;
CC       P06400:RB1; NbExp=3; IntAct=EBI-78670, EBI-491274;
CC       P61964:WDR5; NbExp=5; IntAct=EBI-78670, EBI-540834;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed in brain,
CC       prostate, testis and ovary; weakly expressed in lung, thymus and
CC       small intestine.
CC   -!- DOMAIN: Contains two Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. Only
CC       motif 1 is essential for the association with nuclear receptors,
CC       while adjacent Ser-884 displays selectivity for nuclear receptors.
CC   -!- PTM: Phosphorylated by PRKDC.
CC   -!- PTM: Phosphorylation on Ser-884 leads to a strong decrease in
CC       binding to ESR1 and ESR2. {ECO:0000269|PubMed:10823961,
CC       ECO:0000269|PubMed:11773444}.
CC   -!- MISCELLANEOUS: Frequently amplified or overexpressed in colon,
CC       breast and lung cancers.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF16403.1; Type=Frameshift; Positions=88; Evidence={ECO:0000305};
CC       Sequence=BAA11498.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF177388; AAF13595.1; -; mRNA.
DR   EMBL; AF208227; AAF16403.1; ALT_FRAME; mRNA.
DR   EMBL; AF245115; AAF78480.1; -; mRNA.
DR   EMBL; AF128458; AAF37003.1; -; mRNA.
DR   EMBL; AF171667; AAF71829.1; -; mRNA.
DR   EMBL; D80003; BAA11498.2; ALT_INIT; mRNA.
DR   EMBL; AL109824; CAB92721.2; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76254.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76255.1; -; Genomic_DNA.
DR   EMBL; BC136272; AAI36273.1; -; mRNA.
DR   CCDS; CCDS13241.1; -.
DR   RefSeq; NP_001229468.1; NM_001242539.2.
DR   RefSeq; NP_001305169.1; NM_001318240.1.
DR   RefSeq; NP_054790.2; NM_014071.4.
DR   UniGene; Hs.368971; -.
DR   UniGene; Hs.736403; -.
DR   ProteinModelPortal; Q14686; -.
DR   SMR; Q14686; -.
DR   BioGrid; 116691; 81.
DR   DIP; DIP-30934N; -.
DR   IntAct; Q14686; 34.
DR   MINT; MINT-1194462; -.
DR   STRING; 9606.ENSP00000351894; -.
DR   iPTMnet; Q14686; -.
DR   PhosphoSitePlus; Q14686; -.
DR   BioMuta; NCOA6; -.
DR   DMDM; 116242672; -.
DR   EPD; Q14686; -.
DR   MaxQB; Q14686; -.
DR   PaxDb; Q14686; -.
DR   PeptideAtlas; Q14686; -.
DR   PRIDE; Q14686; -.
DR   Ensembl; ENST00000359003; ENSP00000351894; ENSG00000198646.
DR   Ensembl; ENST00000374796; ENSP00000363929; ENSG00000198646.
DR   GeneID; 23054; -.
DR   KEGG; hsa:23054; -.
DR   UCSC; uc002xav.3; human.
DR   CTD; 23054; -.
DR   DisGeNET; 23054; -.
DR   GeneCards; NCOA6; -.
DR   H-InvDB; HIX0015752; -.
DR   HGNC; HGNC:15936; NCOA6.
DR   HPA; HPA004198; -.
DR   HPA; HPA050211; -.
DR   MIM; 605299; gene.
DR   neXtProt; NX_Q14686; -.
DR   OpenTargets; ENSG00000198646; -.
DR   PharmGKB; PA31475; -.
DR   eggNOG; ENOG410IK20; Eukaryota.
DR   eggNOG; ENOG410XW4F; LUCA.
DR   GeneTree; ENSGT00730000111114; -.
DR   HOVERGEN; HBG052586; -.
DR   InParanoid; Q14686; -.
DR   KO; K14971; -.
DR   OMA; PAMTGIP; -.
DR   OrthoDB; EOG091G00CR; -.
DR   PhylomeDB; Q14686; -.
DR   TreeFam; TF332639; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   ChiTaRS; NCOA6; human.
DR   GeneWiki; NCOA6; -.
DR   GenomeRNAi; 23054; -.
DR   PRO; PR:Q14686; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000198646; -.
DR   CleanEx; HS_NCOA6; -.
DR   ExpressionAtlas; Q14686; baseline and differential.
DR   Genevisible; Q14686; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0035097; C:histone methyltransferase complex; IDA:MGI.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; TAS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; TAS:UniProtKB.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcription coactivator activity; IPI:UniProtKB.
DR   GO; GO:0046965; F:retinoid X receptor binding; TAS:UniProtKB.
DR   GO; GO:0046966; F:thyroid hormone receptor binding; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0007420; P:brain development; ISS:UniProtKB.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:MGI.
DR   GO; GO:0006310; P:DNA recombination; NAS:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; NAS:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; NAS:UniProtKB.
DR   GO; GO:0006352; P:DNA-templated transcription, initiation; IDA:UniProtKB.
DR   GO; GO:0042921; P:glucocorticoid receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0030520; P:intracellular estrogen receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0030099; P:myeloid cell differentiation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; TAS:UniProtKB.
DR   GO; GO:0009725; P:response to hormone; TAS:UniProtKB.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; ISS:UniProtKB.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR032715; NCOA6_nucleic_acid-bd.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   Pfam; PF13820; Nucleic_acid_bd; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Complete proteome; Methylation; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transcription; Transcription regulation.
FT   CHAIN         1   2063       Nuclear receptor coactivator 6.
FT                                /FTId=PRO_0000094413.
FT   REGION        1   1310       NCOA1-binding region.
FT   REGION        1   1057       CREBBP-binding region.
FT   REGION        1    928       TBP/GTF2A-binding region.
FT   REGION      773    927       NCOA6IP-binding region.
FT   REGION     1641   2063       EP300/CRSP3-binding region.
FT   MOTIF       887    891       LXXLL motif 1.
FT   MOTIF      1491   1495       LXXLL motif 2.
FT   COMPBIAS    227   1041       Gln-rich.
FT   COMPBIAS    372    377       Poly-Pro.
FT   COMPBIAS    913    918       Poly-Lys.
FT   MOD_RES      95     95       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     884    884       Phosphoserine; by MAPK; in vitro.
FT                                {ECO:0000269|PubMed:11773444}.
FT   MOD_RES    1047   1047       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q9JL19}.
FT   MOD_RES    1058   1058       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q9JL19}.
FT   MOD_RES    1096   1096       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q9JL19}.
FT   MOD_RES    1321   1321       Phosphothreonine.
FT                                {ECO:0000269|PubMed:10823961}.
FT   MOD_RES    1819   1819       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9JL19}.
FT   MOD_RES    1822   1822       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9JL19}.
FT   MOD_RES    2018   2018       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT     512    512       P -> L (in dbSNP:rs6060031).
FT                                /FTId=VAR_027874.
FT   VARIANT     955    955       N -> S (in dbSNP:rs17092079).
FT                                {ECO:0000269|PubMed:10567404,
FT                                ECO:0000269|PubMed:10681503,
FT                                ECO:0000269|PubMed:10823961,
FT                                ECO:0000269|PubMed:10866662,
FT                                ECO:0000269|PubMed:8724849}.
FT                                /FTId=VAR_027875.
FT   VARIANT    1060   1060       P -> S (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036551.
FT   VARIANT    1191   1191       S -> R (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036552.
FT   VARIANT    1995   1995       I -> V (in dbSNP:rs6060022).
FT                                /FTId=VAR_027876.
FT   MUTAGEN     883    894       TSPLLVNLLQSD->ENPLLVNLLQFI: Reduced
FT                                binding to THRB, RXRA, ESR2 and ESR1.
FT                                {ECO:0000269|PubMed:11773444}.
FT   MUTAGEN     883    894       TSPLLVNLLQSD->NLPLLVNLLQHT: Reduced
FT                                binding to THRB, RXRA, ESR2 and ESR1.
FT                                {ECO:0000269|PubMed:11773444}.
FT   MUTAGEN     883    894       TSPLLVNLLQSD->VNPLLVNLLQFI: Reduced
FT                                binding to THRB, RXRA, ESR2 and ESR1.
FT                                {ECO:0000269|PubMed:11773444}.
FT   MUTAGEN     883    884       TS->SY: Strong increase in binding to
FT                                THRB, RXRA and ESR2, but dramatic
FT                                decrease in binding to ESR1.
FT   MUTAGEN     884    894       SPLLVNLLQSD->NPLLVNLLQLL: Reduced binding
FT                                to THRB, RXRA, ESR2 and ESR1.
SQ   SEQUENCE   2063 AA;  219145 MW;  73219502F5138427 CRC64;
     MVLDDLPNLE DIYTSLCSST MEDSEMDFDS GLEDDDTKSD SILEDSTIFV AFKGNIDDKD
     FKWKLDAILK NVPNLLHMES SKLKVQKVEP WNSVRVTFNI PREAAERLRI LAQSNNQQLR
     DLGILSVQIE GEGAINLALA QNRSQDVRMN GPMGAGNSVR MEAGFPMASG PGIIRMNNPA
     TVMIPPGGNV SSSMMAPGPN PELQPRTPRP ASQSDAMDPL LSGLHIQQQS HPSGSLAPPH
     HPMQPVSVNR QMNPANFPQL QQQQQQQQQQ QQQQQQQQQQ QQQQQLQARP PQQHQQQQPQ
     GIRPQFTAPT QVPVPPGWNQ LPSGALQPPP AQGSLGTMTA NQGWKKAPLP GPMQQQLQAR
     PSLATVQTPS HPPPPYPFGS QQASQAHTNF PQMSNPGQFT APQMKSLQGG PSRVPTPLQQ
     PHLTNKSPAS SPSSFQQGSP ASSPTVNQTQ QQMGPRPPQN NPLPQGFQQP VSSPGRNPMV
     QQGNVPPNFM VMQQQPPNQG PQSLHPGLGG MPKRLPPGFS AGQANPNFMQ GQVPSTTATT
     PGNSGAPQLQ ANQNVQHAGG QGAGPPQNQM QVSHGPPNMM QPSLMGIHGN MNNQQAGTSG
     VPQVNLSNMQ GQPQQGPPSQ LMGMHQQIVP SQGQMVQQQG TLNPQNPMIL SRAQLMPQGQ
     MMVNPPSQNL GPSPQRMTPP KQMLSQQGPQ MMAPHNQMMG PQGQVLLQQN PMIEQIMTNQ
     MQGNKQQFNT QNQSNVMPGP AQIMRGPTPN MQGNMVQFTG QMSGQMLPQQ GPVNNSPSQV
     MGIQGQVLRP PGPSPHMAQQ HGDPATTANN DVSLSQMMPD VSIQQTNMVP PHVQAMQGNS
     ASGNHFSGHG MSFNAPFSGA PNGNQMSCGQ NPGFPVNKDV TLTSPLLVNL LQSDISAGHF
     GVNNKQNNTN ANKPKKKKPP RKKKNSQQDL NTPDTRPAGL EEADQPPLPG EQGINLDNSG
     PKLPEFSNRP PGYPSQPVEQ RPLQQMPPQL MQHVAPPPQP PQQQPQPQLP QQQQPPPPSQ
     PQSQQQQQQQ QQMMMMLMMQ QDPKSVRLPV SQNVHPPRGP LNPDSQRMPM QQSGSVPVMV
     SLQGPASVPP SPDKQRMPMP VNTPLGSNSR KMVYQESPQN PSSSPLAEMA SLPEASGSEA
     PSVPGGPNNM PSHVVLPQNQ LMMTGPKPGP SPLSATQGAT PQQPPVNSLP SSHGHHFPNV
     AAPTQTSRPK TPNRASPRPY YPQTPNNRPP STEPSEISLS PERLNASIAG LFPPQINIPL
     PPRPNLNRGF DQQGLNPTTL KAIGQAPSNL TMNPSNFATP QTHKLDSVVV NSGKQSNSGA
     TKRASPSNSR RSSPGSSRKT TPSPGRQNSK APKLTLASQT NAALLQNVEL PRNVLVSPTP
     LANPPVPGSF PNNSGLNPQN STVSVAAVGG VVEDNKESLN VPQDSDCQNS QSRKEQVNIE
     LKAVPAQEVK MVVPEDQSKK DGQPSDPNKL PSVEENKNLV SPAMREAPTS LSQLLDNSGA
     PNVTIKPPGL TDLEVTPPVV SGEDLKKASV IPTLQDLSSS KEPSNSLNLP HSNELCSSLV
     HPELSEVSSN VAPSIPPVMS RPVSSSSIST PLPPNQITVF VTSNPITTSA NTSAALPTHL
     QSALMSTVVT MPNAGSKVMV SEGQSAAQSN ARPQFITPVF INSSSIIQVM KGSQPSTIPA
     APLTTNSGLM PPSVAVVGPL HIPQNIKFSS APVPPNALSS SPAPNIQTGR PLVLSSRATP
     VQLPSPPCTS SPVVPSHPPV QQVKELNPDE ASPQVNTSAD QNTLPSSQST TMVSPLLTNS
     PGSSGNRRSP VSSSKGKGKV DKIGQILLTK ACKKVTGSLE KGEEQYGADG ETEGQGLDTT
     APGLMGTEQL STELDSKTPT PPAPTLLKMT SSPVGPGTAS AGPSLPGGAL PTSVRSIVTT
     LVPSELISAV PTTKSNHGGI ASESLAGGLV EEKVGSHPEL LPSIAPSQNL VSKETSTTAL
     QASVARPELE VNAAIVSGQS SEPKEIVEKS KIPGRRNSRT EEPTVASESV ENGHRKRSSR
     PASASSSTKD ITSAVQSKRR KSK
//
